Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: $FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 4D Molecular Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 4D Molecular Therapeutics's position in the market.
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced that the U.S. FDA granted Rare Pediatric Disease Designation for aerosolized 4D-710, a treatment for cystic fibrosis lung disease. Promising clinical trial results showed significant CFTR expression levels and improved quality of life for patients. The company is also planning an interim data update and pivotal trial planning update for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
-
Rhea-AI Summary
TurnCare, a leading medical technology and services company dedicated to advancing how hospitals manage high acuity patients, proudly announces the addition of John F. Milligan, Ph.D., investor, innovator, and former CEO of Gilead, to its Board of Directors. Dr. Milligan's expertise includes driving major acquisitions to create unique industry solutions and scaling Gilead to over $21 Billion in worldwide sales with a market cap of $85 Billion. He brings a unique and valuable perspective that will help TurnCare maximize the impact of its novel patient management technologies as it scales to more networks, hospitals, and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
-
News
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced clinical pipeline progress, partnership with Arbor Biotechnologies, and organizational updates. The company ended 2023 with $300 million in estimated cash, expecting to fund operations into H1 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT) and Arbor Biotechnologies, Inc. (Arbor) have announced a strategic partnership to co-develop and co-commercialize up to six AAV-delivered CRISPR/Cas-based therapeutic candidates for central nervous system (CNS) diseases with high unmet medical needs. The initial product candidate will target amyotrophic lateral sclerosis (ALS), with additional targets expected to be in diseases with high unmet needs in both rare and large patient populations. The costs and profits will be shared evenly between the two companies, and Arbor will lead the research, development, and commercialization efforts on the first product candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
-
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced the FDA granting RMAT designation for their genetic medicine candidate 4D-150 for wet age-related macular degeneration (wet AMD). The designation follows interim Phase 1 PRISM clinical data demonstrating safety, tolerability, and clinical activity. 4D-150 has potential to address unmet medical needs and reduce treatment burden for wet AMD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.35%
Tags
-
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced the presentation of initial interim landmark data analysis from the Phase 2 PRISM clinical trial at the Angiogenesis, Exudation, and Degeneration 2024 Conference. The data will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the trial, on February 3, 2024. The trial focuses on 4D-150, a treatment for high need patients with neovascular age-related macular degeneration (nAMD). The company will also host a webcast to discuss the data and provide a program update for 4D-150.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
Rhea-AI Summary
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) announced their participation in the 6th Annual Evercore ISI HealthCONx Conference on November 28, 2023, including a fireside chat and one-on-one meetings with the management team. The event will be webcasted and archived for up to a year on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
-
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) reported rapid advancements in the development of 4D-150 for wet age-related macular degeneration (wet AMD), including completing enrollment of PRISM Phase 2 Dose Expansion ahead of schedule, receiving PRIME designation from the European Medicines Agency, and presenting positive interim data from 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis. The company also gained alignment with FDA on the plan to lift clinical hold on 4D-310 for Fabry disease cardiomyopathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.24%
Tags
-
Rhea-AI Summary
4D Molecular Therapeutics announces interim data from the Phase 1/2 AEROW clinical trial evaluating aerosolized 4D-710 for cystic fibrosis lung disease. The treatment was well tolerated with no inflammation observed in lung biopsies. CFTR expression significantly exceeded normal levels in all participants, showing durable clinical activity. FDA feedback on development path expected in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
Rhea-AI Summary
4D Molecular Therapeutics has reached an agreement with the FDA to lift the clinical hold on the Phase 1/2 INGLAXA clinical trial for 4D-310, a treatment for Fabry disease cardiomyopathy. The company has shared the most up-to-date clinical activity and safety data with the FDA and plans to submit the results of a non-clinical study evaluating the safety and biodistribution of 4D-310 to the FDA in Q2 2024. The INGLAXA trial protocol has been amended to minimize the risk of atypical hemolytic uremic syndrome (aHUS) by requiring an immunosuppressive regimen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
4D Molecular Therapeutics, Inc.
Nasdaq:FDMT
FDMT Rankings
FDMT Stock Data
1.37B
31.64M
3.53%
85.52%
18.72%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
EMERYVILLE
About FDMT
the mission of 4d molecular therapeutics is to design and develop transformative gene therapy products using our proprietary technology to create novel adeno-associated virus variants to be utilized as treatments for serious unmet medical conditions. our products are unlocking the full potential of gene therapy to treat, and potentially cure, genetic diseases. a large number of patients and diseases, who previously were not treatable by gene therapy, will be addressable by 4d products. 4d has one of the deepest and most diverse product pipelines in the gene therapy field. adeno-associated virus (aav) vectors have emerged as a favored delivery vehicle for gene therapy in the human body. they can deliver the genes for therapeutic proteins to accessible tissues in the body and are generally considered safe. several aav gene therapy products are in late-stage clinical development, and one product is approved in the eu (glybera, uniqure). however, these first-generation aav vectors have lim